Update on HIV viral-load assays: New technologies and testing in resource-limited settings

Future Virology

Volumn 4, Issue 5, 2009, Pages 423-430

  De Mendoza, Carmen ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Dried blood spots; HIV; HIV subtypes; HIV RNA; Real time PCR; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 73849119255     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.24     Document Type: Article

References (51)

1. Chun T, Fauci A: Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl Acad. Sci. USA 96, 10958-10961 (1999).
2. Sandstrom E, Kaplan J: Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. Drugs 34, 372-390 (1987).
3. Mellors J, Rinaldo C, Gupta P et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170 (1996).
4. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126, 946-954 (1997). ■■ Pivotal study demonstrating the independent prognostic value of plasma HIV-RNA on clinical progression to AIDS.
5. Hammer S, Eron J, Reiss P et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300, 555-570 (2008).
6. Aoki-Sei S, Yarchoan R, Kageyama S et al.: Plasma HIV-1 viremia in HIV-1 infected individuals assesses by polymerase chain reaction. AIDS Res. Hum. Retroviruses 8, 1263-1270 (1992).
7. Wittek M, Sturmer M, Doerr H, Berger A: Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev. Mol. Diagn. 7, 237-246 (2007).
8. de Mendoza C, Koppelman M, Montes B et al.: Multicenter evaluation of the NucliSENS EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J. Virol. Methods 127, 54-59 (2005).
9. Tang N, Huang S, Salituro J et al.: A real time HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and N samples. J. Virol. Methods 146, 236-245 (2007).
10. Ruelle J, Jnaoui K, Lefevre I, Lamarti N, Goubau P: Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J. Clin. Virol. 44, 297-301 (2009).
11. Garrido C, Zahonero N, Corral A et al.: Correlation between HIV-1 RNA measurements obtained with dried blood spots and those obtained with plasma by use of NucliSENS EasyQ HIV-1 and Abbott Real-Time HIV load test. J. Clin. Microbiol. 47, 1031-1036 (2009). ■ One of the first studies demonstrating the good correlation between viral load measurements in plasma and material drawn from dried blood spots using different methods.
12. Katsoulidou A, Petrodaskalaki M, Sypsa E et al.: Evaluation of the clinical sensitivity for the quantification of HIV-1 RNA in plasma: comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays - LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. J. Virol. Methods 131, 168-174 (2006).
13. Yao J, Liu Z, Ko L et al.: Quantitative detection of HIV-1 RNA using NucliSENS EasyQ HIV-1 assay. J. Virol. Methods 129, 40-46 (2005).
14. Scott L, Noble L, Moloi J et al.: An evaluation of the Abbott m2000 Real-Time HIV-1 assay for HIV viral load monitoring in South Africa compared with existing technologies: Roche COBAS Ampliprep/COBAS Amplicor; Roche COBAS Ampliprep/COBAS TaqMan HIV-1, and bioMérieux NucliSENS EasyQ HIV-1. J. Clin. Microbiol. 47(7), 2209-2217 (2009).
15. Rouet F, Rouzioux C: HIV-1 viral load testing cost in developing countries: what's new? Expert Rev. Mol. Diagn. 7, 703-707 (2007).
16. Weusten J, Carpay W, Oosterlaken T et al.: Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons. Nucleic Acids Res. 30, e26 (2002).
17. Sloma C, Germer J, Gerads T et al.: Comparison of the Abbott RealTime HIV-1 assay to the COBAS AmpliPrep/COBAS TaqMan HIV-1 test: workflow, reliability and direct costs. J. Clin. Microbiol. 47, 889-895 (2009).
18. Fiscus S, Cheng B, Crowe S et al.: HIV-1 viral load assays for resource-limited settings. PLoS Med. 10, 1743-1750 (2006).
19. Cheng B, Landay A, Miler V: Research needs and challenges in the development of HIV diagnostic and treatment monitoring test for use in resource-limited settings. Curr. Opin. HIV AIDS 3, 495-503 (2008).
20. Taylor B, Sobieszczyk M, McCutchan F, Hammer S: The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358, 1590-1602 (2008).
21. Perrin L, Kaiser L, Yerly S: Travel and the spread of HIV-1 genetic variants. Lancet Infect. Dis. 3, 22-27 (2003).
22. de Mendoza C, Rodriguez C, Colomina J et al.: Resistance to non-nucleoside reverse transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin. Infect. Dis. 41, 1350-1354 (2005).
23. Yebra G, Rivas P, Herrero MD et al.: Clinical differences and viral diversity between newly HIV type 1-diagnosed African and non-African patients in Spain (2005-2007). AIDS Res. Hum. Retroviruses 25, 37-44 (2009).
24. Brodine S, Starkey M, Shaffer R: Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 17, 2521-2527 (2003).
25. Lam H, Chen J, Wong K et al.: Evaluation of NucliSENS EasyQ HIV-1 assay for quantification of HIV-1 subtypes prevalent in South-east Asia. J. Clin. Virol. 38, 39-43 (2007).
26. Lin C, Wagner C, Nicol S et al.: Performance of new VERSANT HIV-1 RNA 1.0 assay (kPCR). Presented at: 11th European AIDS Conference. Madrid, Spain, 24-27 October 2007 (Abstract).
27. Holguín A, López M, Molinero M and Soriano V: Performance of three commercial viral load assays, VERSNAT HIV-1 RNA bDNA v3.0, COBAS AmpliPrep/COBAS TaqMan HIV-1, and NucliSENS HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J. Clin. Microbiol. 46, 2918-2923 (2008). ■ Study reporting differences in the performance of distinct viral-load assays testing different HIV-1 non-B subtypes.
28. Korn K, Weissbrich B, Henke-Gendo C et al.: Single-point mutations causing more than 100-fold underestimation of HIV-1 load with the COBAS TaqMan HIV-1 real-time PCR assay. J. Clin. Microbiol. 47, 1238-1240 (2009).
29. Kim J, Beckthold B, Chen Z et al.: Identification of a novel HIV Type 1 subtype H/J recombinant in Canada with discordant HIV viral load (RNA) values with three different commercial assays. AIDS Res. Hum. Retroviruses 23, 1309-1313 (2007).
30. Assefa Y, Jerene D, Lulseged S, Ooms G, Van Damme W: Rapid scale-up of antiretroviral treatment in Ethiopia: successes and system-wide effects. PLoS Med. 4, e1000056 (2009).
31. Lambert J, Harris D, Stiehm E et al.: Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J. Acquir. Immune Defic. Syndr. 34, 512-519 (2003).
32. Ledergerber B, Lundgren J, Walker A et al.: Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364, 51-62 (2004).
33. Tomasoni L, Patroni A, Torti C et al.: Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch. HIV Clin. Trials 4, 311-323 (2003).
34. Murri R, Lepri A, Cicconi P et al.: Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study. J. Acquir. Immune Defic. Syndr. 41, 23-30 (2006).
35. Cassol S, Gill M, Pilon R et al.: Quantification of HIV type 1 RNA from dried plasma spots collected on filter paper. J. Clin. Microbiol. 35, 2795-2801 (1997).
36. + lymphocyte counts in HIV-1-infected patients. Lancet 362, 1459-1460 (2003).
37. Sarge-Njie R, Schim Van Der Loeff M, Ceesay S et al.: Evaluation of the dried blood spot filter paper technology and five testing strategies of HIV-1 and HIV-2 infections in West Africa. Scand. J. Infect. Dis. 38, 1050-1056 (2006).
38. Lakshmi V, Sudha T, Bhanurekha M, Dandona L: Evaluation of the Murex HIV Ag/Ab combination assay when used with dried blood spots. Clin. Microbiol. Infect. 13, 1134-1136 (2007).
39. Masciotra S, Garrido C, Youngpairoj A et al.: High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 21, 2503-2511 (2007).
40. Bertagnolio S, Soto-Ramirez L, Pilon R et al.: HIV-1 drug resistance surveillance using dried whole blood spots. Antivir. Ther. 12, 107-113 (2007).
41. Koal T, Burhenne H, Römling R et al.: Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19, 2995-3001 (2005).
42. Amellal B, Katlama C, Calvez V: Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification. HIV Med. 8, 396-400 (2007).
43. Ayele W, Schuurman R, Messele T et al.: Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of HIV type 1 burden. J. Clin. Microbiol. 45, 891-896 (2007).
44. Brambilla D, Jennings C, Aldrovandi G et al.: Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for HIV RNA: measurement, precision, and RNA stability. J. Clin. Microbiol. 41, 1888-1893 (2003).
45. Mehta N, Trzmielina S, Nonyane B et al.: Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR. PLoS One 4, e5819 (2009).
46. Bennett D, Bertagnolio S, Sutherland D, Gilks C: The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 13, 1-13 (2008). ■ Comprehensive guidelines for antiretroviral drug resistance testing in resource-poor settings.
47. Bertagnolio S, Derdelinckx I, Parker M et al.: World Health Organization/HIVResNet drug resistance laboratory strategy. Antivir. Ther. 13, 49-57 (2008).
48. The circulating recombinant forms (CRFs). HIV sequence Los Alamos database. www.hiv.lanl.gov
49. WHO/UNAIDS/UNICEF. Towards universal access. Scaling up priority HIV/ AIDS intervention in the health sector. Progress report, June 2008. www.who.int/hiv/pub/2008progressreport/en/
50. WHO. Transaction prices for antiretroviral medicines and HIV diagnostics from 2004 to September 2008. Summary report from the global price reporting mechanism. www.who.int/hiv/amds/ GPRMsummaryReportOct2008.pdf
51. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva, 2006. www.who.int/hiv